Tezspire Shows Promise in Treating Eosinophilic Esophagitis with Positive Phase III Results

AstraZeneca and Amgen's Tezspire (tezepelumab) has shown positive Phase III results in a trial for treating eosinophilic esophagitis (EoE), a chronic inflammatory disorder affecting over 470,000 people in the US. The study found that Tezspire demonstrated statistically significant and clinically meaningful improvements across both co-primary endpoints at week 24, which were sustained through week 52 in both doses tested.

The CROSSING trial was a randomized, double-blind trial that evaluated the efficacy and safety of Tezspire administered subcutaneously every four weeks compared to placebo in adults and adolescents with symptomatic and uncontrolled EoE while on maintenance therapy. The co-primary endpoints were histologic remission and the frequency and severity of dysphagia (difficulty swallowing) compared to placebo.

According to Arjan Bredenoord, a gastroenterologist and professor at the Amsterdam University Medical Center, 'the impressive results from the CROSSING trial sustained over 52 weeks demonstrate that tezepelumab, taken every four weeks, could provide a new approach to treating this disease, with the potential to help more patients achieve remission and symptom improvement.'

Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, said 'the positive results of the Phase III CROSSING trial reinforce our confidence in the differentiated mechanism of action of Tezspire'.